• Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic

    7 days ago - By Xconomy

    Keros Therapeutics, a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult. The Lexington, MA-based company, is a clinical-stage biotech that aims to develop new treatments for patients with blood and musculoskeletal disorders by developing drugs that inhibit a family of proteins called TGF-beta. TGF-beta signaling pathways play a key role in regulating red blood cell and platelet production as well growth, repair, and maintenance of muscle and bone. In its prospectus , Keros...
    Read more ...